HomeRecursion Pharmaceuticals stock forecast
The Recursion Pharmaceuticals stock forecast, using LSEG data, summarises the latest analyst ratings, price targets, and market sentiment for RRSX.
The Recursion Pharmaceuticals stock forecast, using LSEG data, summarises the latest analyst ratings, price targets, and market sentiment for RRSX.
Discover what analysts expect for Recursion Pharmaceuticals's share price outlook in 2025.
Forecast figures are sourced from LSEG and are for informational purposes only. This is not investment advice. Past performance is not a reliable indicator of future results.
Based on 8 analysts, Recursion Pharmaceuticals (RXRX) holds a HOLD consensus rating.
If a majority of analysts rate RXRX as a Buy or Strong Buy, sentiment is broadly positive. If most analysts rate it Hold, sentiment is neutral, suggesting limited short-term momentum. If Sell or Strong Sell dominates, analysts currently see downside potential. These opinions may change over time and should not be taken as investment advice.
The average 12-month Recursion Pharmaceuticals stock forecast is $7.
According to LSEG data, Recursion Pharmaceuticals share price forecasts indicate a 12-month price range between $3 and $11.
While short-term movements are normal, the average analyst target suggests longer-term expectations towards $7.
Past performance is not a reliable indicator of future results.
The current consensus rating is HOLD, according to LSEG analyst data.
The average 12-month analyst price target for RXRX is $7, according to aggregated third-party data.
The highest 12-month target for RXRX (most optimistic) stands at $11.
The most cautious analyst estimate places RXRX at $3 over the next year.
